Last reviewed · How we verify
Neomycin Oral Product
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Used for Suppression of intestinal bacterial flora, Hepatic encephalopathy, Traveler's diarrhea prophylaxis.
At a glance
| Generic name | Neomycin Oral Product |
|---|---|
| Also known as | Neo-Fradin |
| Sponsor | South Australian Health and Medical Research Institute |
| Drug class | Aminoglycoside antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Neomycin works by irreversibly binding to the bacterial 30S ribosomal subunit, disrupting the translation of mRNA into proteins and ultimately causing bacterial cell death. As an oral formulation, it is poorly absorbed from the gastrointestinal tract and acts locally within the gut, making it useful for reducing intestinal bacterial flora. This mechanism makes it effective for pre-operative bowel sterilization and treatment of certain gastrointestinal infections.
Approved indications
- Pre-operative bowel sterilization
- Hepatic encephalopathy (adjunctive therapy)
- Bacterial gastroenteritis
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal cramping
Key clinical trials
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- Antibiotics and Vaccine Immune Responses Study (PHASE4)
- Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery (PHASE4)
- A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 (PHASE1)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neomycin Oral Product CI brief — competitive landscape report
- Neomycin Oral Product updates RSS · CI watch RSS
- South Australian Health and Medical Research Institute portfolio CI